癌症免疫学和溶瘤病毒学：技术和全球市场

报告亮点

The global cancer immunotherapies market reached $30.8 billion in 2012. This market is expected to grow to nearly $34.3 billion in 2013 and $67.9 billion in 2018 with a compound annual growth rate (CAGR) of 14.7% over the five-year period, 2013 to 2018.

Report Includes

• 全球癌症免疫疗法市场的概述
• 对全球市场趋势的分析，包括2012年的数据，2013年的估算以及CAGR的预测到2018年。
• Analyses of factors influencing market demand such as clinical guidelines, demographic changes, and market saturation
• Technological discussion including the current state, newly issued patents, and pending applications
• Profiles of leading companies in the industry.

SCOPE OF REPORT

The scope of this study entails the current immunology therapeutics markets for several of the most common cancers. The sectors covered are colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines and other cancer treatment immunology products. Vaccines against HPV and hepatitis B are included; while such vaccines act only indirectly against cancer, they do serve to protect against the disease. Also covered is oncolytic virology, so new that its market tables have been presented separately from the immunotherapy tables. The report also includes discussion of the regulatory environment, current and developing technologies, cancer incidence, market projections and market share, along with latest trends and clinical trials.

分析师证书

Valerie Kellogg is an experienced medical device and pharmaceutical professional with international market research experience. She has authored numerous reports on topics ranging from treatment of obesity to ablation devices, from wound care to treatment of chronic migraine. Her strong focus areas include treatment of chronic disease, the latest in surgical devices and analysis of potential acquisitions.